Richard M. Simon
#173,079
Most Influential Person Now
Richard M. Simon's AcademicInfluence.com Rankings
Richard M. Simonmathematics Degrees
Mathematics
#7776
World Rank
#10556
Historical Rank
Statistics
#977
World Rank
#1072
Historical Rank
Download Badge
Mathematics
Richard M. Simon's Degrees
- PhD Biostatistics University of Washington
Why Is Richard M. Simon Influential?
(Suggest an Edit or Addition)Richard M. Simon's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. (1996) (881)
- Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. (2007) (645)
- Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. (1980) (450)
- Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. (1999) (371)
- Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. (1978) (303)
- Trends in reported incidence of primary malignant brain tumors in children in the United States. (1998) (301)
- Protected environments and prophylactic antibiotics. A prospective controlled study of their utility in the therapy of acute leukemia. (1973) (284)
- The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. (1978) (274)
- A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. (1985) (240)
- Histologic progression in non-Hodgkin's lymphoma. (1982) (238)
- The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. (2013) (231)
- A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy (1978) (230)
- Prognostic factors for advanced diffuse histiocytic lymphoma following treatment with combination chemotherapy. (1977) (228)
- Duration of empiric antibiotic therapy in granulocytopenic patients with cancer. (1979) (225)
- Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma. (1998) (219)
- A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. (1986) (218)
- Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. (1979) (217)
- Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. (2011) (209)
- Delata-9-tetrahydrocannabinol as an antiemetic in cancer patients receiving high-dose methotrexate. A prospective, randomized evaluation. (1979) (208)
- Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. (1991) (187)
- Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. (1979) (181)
- An autopsy study of histologic progression in non‐Hodgkin's lymphomas 192 cases from the national cancer institute (1983) (156)
- Estrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. (1980) (144)
- "Concentration x time" methotrexate via a subcutaneous reservoir: a less toxic regimen for intraventricular chemotherapy of central nervous system neoplasms. (1978) (140)
- Therapeutic response in phase I trials of antineoplastic agents. (1986) (133)
- Prospective randomized evaluation of the role of limb-sparing surgery, radiation therapy, and adjuvant chemoimmunotherapy in the treatment of adult soft-tissue sarcomas. (1978) (131)
- Association between steroid hormone receptor status and disease-free interval in breast cancer. (1979) (123)
- Prognostic factors in Burkitt's lymphoma importance of total tumor burden (1980) (121)
- Advanced ovarian cancer correlation of histologic grade with response to therapy and survival (1980) (117)
- Clinical trial designs for the early clinical development of therapeutic cancer vaccines. (2001) (115)
- Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer (2015) (114)
- Nonparametric confidence limits for survival probabilities and median survival time. (1982) (114)
- Malignant lymphoma I. The histology and staging of 473 patients at the national cancer institute (1982) (112)
- Evaluation of tamoxifen dose in advanced breast cancer: a progress report. (1976) (110)
- Increasing incidence of Gram-positive sepsis in cancer patients. (1978) (108)
- The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. (1988) (107)
- Type IV collagen immunoreactivity in colorectal cancer: Prognostic value of basement membrane deposition (1988) (103)
- Malignant lymphoma II. Prognostic factors and response to treatment of 473 patients at the national cancer institute (1982) (101)
- Biological markers in breast carcinoma: III. Clinical correlations with carcinoembryonic antigen (1977) (94)
- Development and validation of therapeutically relevant multi-gene biomarker classifiers. (2005) (93)
- A staging system for hepatocellular carcinoma: Prognostic factors in Ugandan patients (1975) (90)
- Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis. (1993) (86)
- Combination chemotherapy of advanced lung cancer. A randomized trial (1976) (82)
- Development and evaluation of therapeutically relevant predictive classifiers using gene expression profiling. (2006) (74)
- Estrogen receptor values in patients with benign breast disease (1979) (70)
- Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. (1987) (69)
- Antiemetic studies: a methodological discussion. (1986) (67)
- Nodular histiocytic lymphoma: an aggressive nodular lymphoma with potential for prolonged disease-free survival. (1980) (66)
- Tolerance to antineoplastic agents in children and adults. (1985) (61)
- Biological markers in breast carcinoma: II. Clinical correlations with human chorionic gonadotrophin (1977) (60)
- Estimation of tamoxifen's efficacy for preventing the formation and growth of breast tumors. (2000) (59)
- Evidence that Childhood Acute Lymphoblastic Leukemia is Associated with an Infectious Agent Linked to Hygiene Conditions (1998) (58)
- Statistical model to determine the relationship of response and survival in patients with advanced ovarian cancer treated with chemotherapy. (1992) (58)
- Assessing whether to perform a confirmatory randomized clinical trial. (1996) (58)
- On the Design of Combination Cancer Therapy (2017) (58)
- The biology of tumor growth in the non-Hodgkin's lymphomas. A dual parameter flow cytometry study of 220 cases. (1984) (57)
- Treatment of osteogenic sarcoma. I. Effect of adjuvant high-dose methotrexate after amputation. (1979) (54)
- Natural history of malignant lymphomas with divergent histologies at staging evaluation (1981) (53)
- Cardiac metastases in lung cancer. (1977) (52)
- Relationship between the progesterone, androgen, and glucocorticoid receptor and response rate to endocrine therapy in metastatic breast cancer. (1979) (48)
- Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. (1982) (48)
- Two-stage plans for patient accrual in phase II cancer clinical trials. (1979) (47)
- A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. (2000) (47)
- The Rappaport classification of non-Hodgkin's lymphomas: a closer look using other proposed classifications. (1980) (45)
- Pretreatment serum lactate dehydrogenase predicting metastatic spread in Ewing's sarcoma. (1975) (44)
- Histologic grade in advanced ovarian cancer. (1979) (41)
- Age-specific incidence of acute lymphoblastic leukemia in U.S. children: in utero initiation model. (1997) (38)
- Comparison of four‐combination chemotherapy programs in metastatic breast cancer. Comparison of multiple drug therapy with cytoxan, 5‐fu and prednisone versus cytoxan and adriamycin, versus cytoxan, 5‐Fu and adriamycin, versus cytoxan, 5‐Fu and prednisone alternating with cytoxan and adriamycin (1982) (37)
- An association between steroid hormone receptors and response to cytotoxic chemotherapy in patients with metastatic breast cancer. (1978) (35)
- An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). (2011) (35)
- Treatment of osteogenic sarcoma. II. Aggressive resection of pulmonary metastases. (1979) (35)
- A prospective randomized study of adjuvant parenteral nutrition in the treatment of diffuse lymphoma: effect on drug tolerance. (1981) (34)
- Combination chemotherapy for metastatic breast cancer. Comparison of multiple drug therapy with 5‐fluorouracil, cytoxan and prednisone with adriamycin or adrenalectomy (1978) (31)
- Physiologic response and toxicity in patients undergoing whole-body hyperthermia for the treatment of cancer. (1981) (30)
- HÆMOPOIETIC RECOVERY IN EWING'S SARCOMA AFTER INTENSIVE COMBINATION THERAPY AND AUTOLOGOUS MARROW INFUSION (1980) (29)
- Long‐term second remissions in acute lymphatic leukemia (1975) (29)
- Estimating the number of rate limiting genomic changes for human breast cancer (2005) (27)
- Estrogen receptors and response of breast cancer to chemotherapy. (1978) (24)
- Bone marrow involvement in breast cancer. Effect on response and tolerance to combination chemotherapy (1977) (24)
- Thymosin reconstitution of T cell deficits in vitro in cancer patients (1977) (24)
- Effect of thymosin in vitro on T cell levels during radiation therapy. Correlations with radiation portal and initial T cell levels (1977) (24)
- Effects of 5-fluorouracil on the cell kinetic and growth parameters of hepatoma 3924A. (1975) (21)
- Immunosuppression in burkitt's lymphoma. II. Peripheral blood lymphocyte populations related to clinical status (1976) (21)
- Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma. (1977) (21)
- Analysis and interpretation of response rates for anticancer drugs. (1979) (20)
- Problems of multiplicity in clinical trials (1994) (20)
- A clinical trial of chemotherapy and RAJI immunotherapy in advanced acute lymphatic leukemia. (1975) (19)
- Height, weight, and risk of breast cancer relapse (1985) (18)
- Association between steroid hormone receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. (1978) (17)
- Solid tumor models for the assessment of different treatment modalities: II: rapid, intermediate, and slow growing transplantable rat hepatomas. (1976) (17)
- Prognostic factors for patients with diffuse large cell or immunoblastic non-Hodgkin's lymphomas: experience of the non-Hodgkin's Lymphoma Pathologic Classification Project. (1990) (15)
- 5-fluorouracil versus CCNU in the treatment of metastatic prostatic cancer. (1977) (15)
- Dose intensity analysis in advanced ovarian cancer patients. (1993) (15)
- Lack of therapeutic synergism between vincristine and methotrexate in L1210 murine leukemia in vivo. (1978) (14)
- Discovering the truth about tamoxifen: problems of multiplicity in statistical evaluation of biomedical data. (1995) (14)
- Lack of Prognostic Value of Lymphoblast Size in Acute Lymphoblastic Leukaemia (1976) (13)
- Statistical methods for evaluating pregnancy outcomes in patients with Hodgkin's disease (1980) (12)
- A study of HLA antigens and haplotypes in a population of Caucasians with acute non-lymphocytic leukemia. (1979) (12)
- The role of overviews in cancer therapeutics. (1987) (12)
- Increased incidence rates but no space–Time clustering of childhood astrocytoma in Sweden, 1973–1992 (2000) (11)
- Role of hexamethylmelamine in the treatment of ovarian cancer: where is the needle in the haystack? (1986) (10)
- Children and cancer. A perspective from the cancer therapy evaluation program, national cancer institute (1993) (10)
- Run-in phase III trial design with pharmacodynamics predictive biomarkers. (2013) (10)
- Failure of immunotherapy with neuraminidase-treated tumor cell vaccine in mice bearing established 3-methylcholanthrene-induced sarcomas. (1978) (7)
- Cryopreserved lymphocytes: decreased response in immune assays of a population of sarcoma patients. (1980) (5)
- Evaluating the differential effect of diet on rat carcinogenesis. (1991) (4)
- Relationship between response and survival in patients with advanced ovarian cancer. (1992) (4)
- THE IMPORTANCE OF DURATION OF THERAPY IN ACUTE LYMPHATIC LEUKEMIA (ALL) (1974) (4)
- Evaluation of CCNU (NSC-79037) used for the prevention of CNS involvement in Burkitt's lymphoma. (1975) (4)
- Response: Re: Trends in Reported Incidence of Primary Malignant Brain Tumors in Children in the United States (1999) (3)
- Longitudinal studies of cellular immunity of patients with osteogenic sarcoma during chemoimmunotherapy. (1980) (3)
- A proposed model for the prediction of response to endocrine therapy in breast cancer from the estrogen receptor status of one site and the number of metastatic sites. (1980) (3)
- Delta-9-Tetrahydrocannabinol as an Antiemetic in Cancer Patients Receiving High-Dose Methotrexate (2020) (3)
- Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma? (2011) (3)
- 18 The use of a statistical model to help predict the outcome of phase III trials of patients (pts) with extensive stage small cell lung cancer (ES-SCLC) (1997) (2)
- Diffuse Large B-Cell Lymphoma Subgroups Have Distinct Genetic Profiles that Influence Tumor Biology and Improve Gene Expression-Based Survival Prediction for the Lymphoma/Leukemia Molecular Profiling Project (2005) (2)
- Relationship of tumor response and survival in advanced ovarian cancer patients treated with chemotherapy (1991) (2)
- Phase III trials in patients with advanced stage non-small cell lung cancer: The experience in North America from 1973–1994 (2000) (1)
- Age effects of radiation-associated neurotoxicity in children. (1993) (1)
- The Non-Hodgkin Lymphoma Pathologic Classification Project (2020) (1)
- Different Biological Processes Are Associated with Prognosis and Chemotherapy Sensitivity in the Different Molecular Subtypes of Breast Cancer. (2009) (1)
- Intestinal transit time as an important factor in the pathogenesis of dimethyl-hydrazine-induced rat colon cancer. (1978) (1)
- Guidelines for Reporting Studies of Treatment for Prostatic Cancer (1988) (1)
- Results of Low-Dose Cytosine Arabinoside (Lo-DAC) Therapy in Seven Patients with Acute Lymphocytic Leukemia Patient Sex/Age FAB First-Line First CR Lo.DAC Survivalt Number (years) Type Treatment (months) Dosage* Result (months) (1990) (0)
- Guidelines for the D esign of Clinical Studies for the D evelopment and V alidation of Therapeutically R elevant B iomarkers and B iomarker-B ased Classification Systems (0)
- CHEST , 71 : 5 , MAY , 1977 CARDIAC METASTASES IN LUNG CANCER 601 Cardiac Metastases in Lung Cancer * (2006) (0)
- Cross-platform performance of genes predictive of pathologic response to doxorubicin-paclitaxel containing regimens (2008) (0)
- RESPONSE: Re: A Model to Select Chemotherapy Regimens for Phase III Trials for Extensive-Stage Small-Cell Lung Cancer (2001) (0)
- T-cell levels and response to thymosin in vitro during intensive chemotherapy in cancer patients receiving thymosin. (1977) (0)
- COMMENT ON : TRENDS IN REPORTED INCIDENCE OF PRIMARY MALIGNANT BRAIN TUMORS IN CHILDREN IN THE UNITED STATES. AUTHORS' REPLIES (1999) (0)
- Outcome prediction in estrogen-receptor positive, chemotherapy- and tamoxifen-treated patients with locally advanced breast cancer (2008) (0)
- Cytoxan vepeside adriamycin methotrexate prednisone nitrogen mustard vincristine procarbazine prednisone combination chemo therapy treatment of diffuse lymphomas (1980) (0)
- PSA velocity and prostate cancer. (2004) (0)
- SPECIAL ARTICLE Assessing Whether to Perform a Confirmatory Randomized Clinical Trial (1996) (0)
- Abstract 1879: The exomes of the NCI60 and their implications for cancer pharmacogenomics (2012) (0)
- A Perspective from the Cancer Therapy Evaluation Program, National Cancer Institute (1993) (0)
- Clinical T rial D esigns f or t he E arly C linical D evelopment of T herapeutic C ancer V accines (2001) (0)
This paper list is powered by the following services:
